323 related articles for article (PubMed ID: 35409154)
21. Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.
Spenerova M; Dzubak P; Srovnal J; Radova L; Burianova R; Konecny P; Salkova S; Novak Z; Pospisilova D; Stary J; Blazek B; Hak J; Votava T; Timr P; Kaiserova E; Bubanska E; Mihal V; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):422-7. PubMed ID: 23128824
[TBL] [Abstract][Full Text] [Related]
22. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.
Oliveira ML; Akkapeddi P; Ribeiro D; Melão A; Barata JT
Adv Biol Regul; 2019 Jan; 71():88-96. PubMed ID: 30249539
[TBL] [Abstract][Full Text] [Related]
23. Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: a controlled study comparing prednisone versus dexamethasone in induction phase.
Saracco P; Bertorello N; Farinasso L; Einaudi S; Barisone E; Altare F; Corrias A; Pastore G
J Pediatr Hematol Oncol; 2005 Mar; 27(3):141-4. PubMed ID: 15750445
[TBL] [Abstract][Full Text] [Related]
24. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
Bornhauser BC; Bonapace L; Lindholm D; Martinez R; Cario G; Schrappe M; Niggli FK; Schäfer BW; Bourquin JP
Blood; 2007 Sep; 110(6):2084-91. PubMed ID: 17537996
[TBL] [Abstract][Full Text] [Related]
25. [Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].
Xu JY; Luo JM
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Aug; 19(8):945-949. PubMed ID: 28774373
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
27. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.
Dördelmann M; Reiter A; Borkhardt A; Ludwig WD; Götz N; Viehmann S; Gadner H; Riehm H; Schrappe M
Blood; 1999 Aug; 94(4):1209-17. PubMed ID: 10438708
[TBL] [Abstract][Full Text] [Related]
28. BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma.
Tian XP; Cai J; Ma SY; Fang Y; Huang HQ; Lin TY; Rao HL; Li M; Xia ZJ; Kang TB; Xie D; Cai QQ
Cancer Commun (Lond); 2020 Jun; 40(6):245-259. PubMed ID: 32459053
[TBL] [Abstract][Full Text] [Related]
29. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
30. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
Driessen EM; van Roon EH; Spijkers-Hagelstein JA; Schneider P; de Lorenzo P; Valsecchi MG; Pieters R; Stam RW
Haematologica; 2013 Jun; 98(6):937-44. PubMed ID: 23403319
[TBL] [Abstract][Full Text] [Related]
31. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
[TBL] [Abstract][Full Text] [Related]
32. The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers.
McNeer JL; Nachman JB
Br J Haematol; 2010 Jun; 149(5):638-52. PubMed ID: 20408842
[TBL] [Abstract][Full Text] [Related]
33. α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK).
Naci D; El Azreq MA; Chetoui N; Lauden L; Sigaux F; Charron D; Al-Daccak R; Aoudjit F
J Biol Chem; 2012 May; 287(21):17065-17076. PubMed ID: 22457358
[TBL] [Abstract][Full Text] [Related]
34. Some GCR Polymorphisms (N363S, ER22/23EK, and Bcl-1) May Influence Steroid-induced Toxicities and Survival Rates in Children With ALL.
Eipel O; Hegyi M; Csordás K; Németh K; Luczay A; Török D; Csóka M; Erdélyi D; Kovács G
J Pediatr Hematol Oncol; 2016 Jul; 38(5):334-40. PubMed ID: 27050122
[TBL] [Abstract][Full Text] [Related]
35. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Bostrom BC; Sensel MR; Sather HN; Gaynon PS; La MK; Johnston K; Erdmann GR; Gold S; Heerema NA; Hutchinson RJ; Provisor AJ; Trigg ME;
Blood; 2003 May; 101(10):3809-17. PubMed ID: 12531809
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
37. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
Aricò M; Valsecchi MG; Conter V; Rizzari C; Pession A; Messina C; Barisone E; Poggi V; De Rossi G; Locatelli F; Micalizzi MC; Basso G; Masera G
Blood; 2002 Jul; 100(2):420-6. PubMed ID: 12091331
[TBL] [Abstract][Full Text] [Related]
38. The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia.
Daniel LC; Li Y; Kloss JD; Reilly AF; Barakat LP
Support Care Cancer; 2016 Sep; 24(9):3897-906. PubMed ID: 27108263
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
[TBL] [Abstract][Full Text] [Related]
40. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
